echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Levocetirizine hydrochloride granules, a class 5 new drug of Kangzhi pharmaceutical, has obtained the production approval

    Levocetirizine hydrochloride granules, a class 5 new drug of Kangzhi pharmaceutical, has obtained the production approval

    • Last Update: 2015-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In the afternoon of June 16, Kangzhi pharmaceutical released a notice that the company recently received the registration approval document of levocetirizine hydrochloride granules approved and issued by the State Food and drug administration, which is valid until May 26, 2020 Levocetirizine hydrochloride granules are suitable for children and adults aged 2 years and over The suitable diseases are urticaria, allergic rhinitis, eczema, dermatitis, pruritus, etc At present, the tablets and capsules of the drug have been sold in the domestic market The company said that the approval of the drug further enriched the product category of the company's children's drug and optimized the company's product structure At present, the company has started to arrange production according to the market demand Appendix: announcement of Hainan Kangzhi Pharmaceutical Co., Ltd on obtaining the registration approval document of levocetirizine hydrochloride granules, the company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, without false records, misleading statements or major omissions Hainan Kangzhi Pharmaceutical Co., Ltd (hereinafter referred to as "the company") recently received the registration approval of levocetirizine hydrochloride granules approved and issued by the State Food and drug administration The specific information of the registration approval is as follows: 1 Drug name: levocetirizine hydrochloride granules; 2 Specification: 2.5mg; 3 Approval No.: 2015s00414; 4 Registration classification: chemical medicine category 5; 5 Approval document No.: gyzz h20150042; 6 Validity of drug approval document No.: until May 26, 2020 Levocetirizine hydrochloride granules are suitable for children and adults aged 2 years and over The suitable diseases are urticaria, allergic rhinitis, eczema, dermatitis, pruritus, etc At present, the tablets and capsules of the drug have been sold in the domestic market The approval documents of the drug further enrich the product categories of the company's children's drugs and optimize the product structure of the company At present, the company has started to arrange production according to the market demand, but the specific sales situation of the product in the future may be affected by market environment changes and other factors, with uncertainty Please make careful decisions and pay attention to prevent investment risks It is hereby announced Board of directors of Hainan Kangzhi Pharmaceutical Co., Ltd June 16, 2015
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.